A U.S. advisory panel on Thursday recommended approval of Egalet Corp’s long-acting opioid painkiller, Arymo ER, saying it dulls pain and could deter abuse by addicts seeking a quick high.
The panel recommended that the Food and Drug Administration (FAD) approve the drug and said it deters, but does not eliminate, the risk of abuse if addicts try to snort, chew or inject it.
Source: Reuters
Filed Under: Drug Discovery
